ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
0.4490
-0.0149 (-3.21%)
Apr 25, 2025, 4:00 PM EDT - Market closed
ImmunoPrecise Antibodies Stock Forecast
IPA's stock price has decreased by -63.2% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ImmunoPrecise Antibodies stock have an average target of 4.00, with a low estimate of 3.00 and a high estimate of 5.00. The average target predicts an increase of 790.87% from the current stock price of 0.45.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunoPrecise Antibodies stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +1,013.59% | Apr 11, 2025 |
| Benchmark | Benchmark | Buy Reiterates $3 | Buy | Reiterates | $3 | +568.15% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +1,013.59% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +1,459.02% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $7 | Strong Buy | Maintains | $9 → $7 | +1,459.02% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
25.66M
from 24.52M
Increased by 4.67%
Revenue Next Year
29.30M
from 25.66M
Increased by 14.15%
EPS This Year
-0.64
from -1.06
EPS Next Year
-0.11
from -0.64
Financial currency is CAD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 27.4M | 30.5M | 40.2M | |||
| Avg | 25.7M | 29.3M | 38.7M | |||
| Low | 24.2M | 28.4M | 37.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 11.9% | 18.7% | 37.3% | |||
| Avg | 4.7% | 14.1% | 32.1% | |||
| Low | -1.3% | 10.8% | 28.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.26 | -0.12 | 0.02 |
| Avg | -0.64 | -0.11 | 0.02 |
| Low | -0.99 | -0.11 | 0.02 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.